EP3820573
3-(5-Hýdroxý-1-oxóísóindólín-2-ýl)píperidín-2,6-díón-afleiður og notkun á þeim við meðhöndlun á ÍKAROS-fjölskyldu sinkfingurs-2 (IKZF2)-háðum sjúkdómum
:
EP einkaleyfi í gildi á Íslandi:
8.7.2019:
9.8.2023:
19782691.0
:
25.10.2023:
15.11.2023
:
7.7.2039:
7.7.2026:
31.7.2026
:
3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
8.7.2019
9.8.2023
25.10.2023
15.11.2023
7.7.2026
:
Novartis AG:
Lichtstrasse 35, 4056 Basel, CH
:
ADCOCK, Claire:
Cambridge, Massachusetts 02139, US
:
BONAZZI, Simone:
Cambridge, Massachusetts 02139, US
:
CERNIJENKO, Artiom:
Cambridge, Massachusetts 02139, US
:
LAM, Philip:
Cambridge, Massachusetts 02139, US
:
LINKENS, Kathryn Taylor:
Cambridge, Massachusetts 02139, US
:
MALIK, Hasnain Ahmed:
Cambridge, Massachusetts 02139, US
:
THOMSEN, Noel Marie-France:
Cambridge, Massachusetts 02139, US
:
VISSER, Michael Scott:
Cambridge, Massachusetts 02139, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
201862695920 P:
10.7.2018:
US
:
201962835543 P:
18.4.2019:
US
:
IB2019055804:
8.7.2019
:
A61P 35/00, C07D 401/04, C07D 401/14, A61K 31/454
: 6
: 24.6.2024
: 7.7.2025
: Árnason Faktor ehf.
: 7
: 4.7.2025
: 7.7.2026
: Árnason Faktor ehf.